{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:00:26Z","timestamp":1765609226274},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2003,11,14]],"date-time":"2003-11-14T00:00:00Z","timestamp":1068768000000},"content-version":"vor","delay-in-days":2357,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[1997,6]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>There are few data on the role of prokinetic agents as maintenance therapy in moderately severe reflux oesophagitis despite the high relapse rate of this condition after healing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims:<\/jats:title><jats:p>To determine whether cisapride is more effective than placebo as maintenance therapy after healing of moderate erosive oesophagitis in two respects: first, in preventing symptomatic relapse and preserving quality of life; and, second, in improving oesophageal motor function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients:<\/jats:title><jats:p>Forty\u2010two patients whose grade II\u2013III oesophagitis had been healed with omeprazole were randomized to receive either cisapride 20\u2003mg <jats:italic>nocte<\/jats:italic> or placebo for 6 months. Oesophageal pH\u2003monitoring and manometry were performed before starting maintenance therapy and after 4 weeks, and symptomatic status and quality of life were assessed at weeks 0, 4, 13 and 26.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>After 4 weeks of maintenance therapy, lower oesophageal sphincter pressure improved in the cisapride group (16.4\u201321.9\u2003mmHg, <jats:italic>P<\/jats:italic>\u2003=\u20030.01) but not in the placebo group (25.5\u201322.7\u2003mmHg, <jats:italic>P<\/jats:italic>\u2003=\u20030.2). Oesophageal pH\u2003monitoring showed no significant changes in either group. Sixteen (76%) cisapride patients and 12 (57%) placebo patients withdrew within 4 weeks owing to symptomatic relapse (<jats:italic>P<\/jats:italic>\u2003=\u20030.2). After 26 weeks, 21 (100%) cisapride and 17 (81%) placebo patients had relapsed (log\u2010rank analysis of survival time <jats:italic>P<\/jats:italic>\u2003=\u20030.07). Quality of life parameters deteriorated in both treatment groups to a similar degree.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Maintenance therapy with cisapride 20\u2003mg nocte improves the lower oesophageal sphincter pressure in patients whose oesophagitis has been healed with omeprazole. However, cisapride is no better than placebo in preventing symptomatic relapse or deterioration in quality of life.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.1997.00176.x","type":"journal-article","created":{"date-parts":[[2003,11,14]],"date-time":"2003-11-14T11:46:44Z","timestamp":1068810404000},"page":"487-495","source":"Crossref","is-referenced-by-count":13,"title":["Maintenance therapy with cisapride after healing of erosive oesophagitis: a double\u2010blind placebo\u2010controlled trial"],"prefix":"10.1111","volume":"11","author":[{"given":"N. I.","family":"McDougall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. G. P.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. S. A.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. J.","family":"McFarland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. H. G.","family":"Love","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,11,14]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","unstructured":"HetzelDJ DentJ ReedWD et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology1988;11:903\u201312.","DOI":"10.1016\/0016-5085(88)90162-X"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","unstructured":"GliseHHealing relapse rates and prophylaxis of reflux oesophagitis. Scand J Gastroenterol1989;11(Suppl. 156):57\u201364.","DOI":"10.3109\/00365528909091039"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","unstructured":"BateCM BoothSN CroweJP et al.Omeprazole 10\u2003mg or 20\u2003mg once daily in the prevention of recurrence of reflux oesophagitis. Gut1995;11:492\u20138.","DOI":"10.1136\/gut.36.4.492"},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","unstructured":"McDougallNI JohnstonBT KeeF et al.Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut1996;11:481\u20136.","DOI":"10.1136\/gut.38.4.481"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","unstructured":"DentJ YeomansND Mackinnon\u2003M et al.Omeprazole vs ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut1994;11:590\u20138.","DOI":"10.1136\/gut.35.5.590"},{"key":"e_1_2_1_7_2","unstructured":"LundellL BackmanL EkstromP et al.Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol1991;11:248\u201356."},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","unstructured":"LambertsR Creutzfeldt\u2003W Str\u00fcberHG BrunnerG SolciaELong\u2010term omeprazole therapy in peptic ulcer disease: gastrin endocrine cell growth and gastritis. Gastroenterology1993;11:1356\u201370.","DOI":"10.1016\/0016-5085(93)90344-C"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","unstructured":"LundellL. Long\u2010term treatment of gastro\u2010oesophageal reflux disease with omeprazole. Scand J Gastroenterol1994;11(Suppl. 201):74\u20138.","DOI":"10.3109\/00365529409105368"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","unstructured":"Klinkenberg\u2010KnolEC FestenHPM JansenJBMJ et al.Long\u2010term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med1994;11:161\u20137.","DOI":"10.7326\/0003-4819-121-3-199408010-00001"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","unstructured":"LiebermanDAMedical therapy for chronic reflux esophagitis. Long\u2010term follow\u2010up. Arch Intern Med1987;11:1717\u201320.","DOI":"10.1001\/archinte.147.10.1717"},{"key":"e_1_2_1_12_2","doi-asserted-by":"crossref","unstructured":"CeccatelliP JanssensJ VantrappenG CucchiaraSCisapride restores the decreased lower oesophageal sphincter pressure in reflux patients. Gut1988;11:631\u20135.","DOI":"10.1136\/gut.29.5.631"},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","unstructured":"TytgatGNJ Anker HansenOJ CarlingL GeldofH GliseHEffect of cisapride on relapse of reflux oesophagitis healed with an antisecretory drug. Scand J Gastroenterol1992;11:175\u201383.","DOI":"10.3109\/00365529208999945"},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","unstructured":"ToussaintJ GossuinA Deruyttere\u2003M HubleF DevisGHealing and prevention of relapse of reflux oesophagitis by cisapride. Gut1991;11:1280\u20135.","DOI":"10.1136\/gut.32.11.1280"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","unstructured":"BlumAL AdamiB BouzoMH et al.Effect of cisapride on relapse of esophagitis: a multinational placebo controlled trial in patients healed with an antisecretory drug. Dig Dis Sci1993;11:551\u201360.","DOI":"10.1007\/BF01316514"},{"key":"e_1_2_1_16_2","unstructured":"LittleAG De MeesterTR KirchnerPT O'SullivanGC SkinnerDB. Pathogenesis of esophagitis in patients with gastroesophageal reflux. Surgery1980;11:101\u20137."},{"key":"e_1_2_1_17_2","unstructured":"DaltonCB. Measurements and interpretations. In: Castell DO Richter JE Dalton CB eds. Esophageal Motility Testing. New York: Elsevier 1987: 61\u201378."},{"key":"e_1_2_1_18_2","doi-asserted-by":"crossref","unstructured":"McDougallNI KeeF CollinsJSA McFarlandRJ LoveAHG. Does treatment of esophagitis with omeprazole improve patient quality of life? Gastroenterology1995;11(4): A162 (Abstract).","DOI":"10.1016\/0016-5085(95)23308-3"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","unstructured":"TytgatGNJ BlumAL VerlindenM. Prognostic factors for relapse and maintenance treatment with cisapride in gastro\u2010oesophageal reflux disease. Aliment Pharmacol Ther1995;11:271\u201380.","DOI":"10.1111\/j.1365-2036.1995.tb00381.x"},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","unstructured":"TytgatGNJ. Long term therapy for reflux esophagitis. N Engl J Med1995;11:1148\u201350.","DOI":"10.1056\/NEJM199510263331711"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","unstructured":"PoynardT. Relapse rate of patients after healing of oesophagitis\u2014a prospective study of alginate as self\u2010care treatment for 6 months. Aliment Pharmacol Ther1993;11:385\u201392.","DOI":"10.1111\/j.1365-2036.1993.tb00111.x"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","unstructured":"GilbertRJ DoddsWJ KahrilasPJ HoganWJ LipmanSEffect of cisapride a new prokinetic agent on esophageal motor function. Dig Dis Sci1987;11(12):1331\u20136.","DOI":"10.1007\/BF01296657"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","unstructured":"HollowayRH DowntonJ MitchellB DentJ. Effect of cisapride on postprandial gastro\u2010oesophageal reflux. Gut1989;11:1187\u201393.","DOI":"10.1136\/gut.30.9.1187"},{"key":"e_1_2_1_24_2","doi-asserted-by":"crossref","unstructured":"Inauen\u2003W EmdeC WeberB et al.Effects of ranitdine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24 hour ambulatory combined pH\u2003and manometry study. Gut1993;11:1025\u201331.","DOI":"10.1136\/gut.34.8.1025"},{"key":"e_1_2_1_25_2","doi-asserted-by":"crossref","unstructured":"BrazierJE HarperR JonesNMB et al. Validating the SF\u201036 health survey questionnaire: new outcome measure for primary care. Br Med J1992;11:160\u20134.","DOI":"10.1136\/bmj.305.6846.160"},{"key":"e_1_2_1_26_2","doi-asserted-by":"crossref","unstructured":"KusterE RosE Toledo\u2010PimentelV et al. Predictive factors of the long term outcome in gastro\u2010oesophageal reflux disease: six year follow up of 107 patients. Gut1994;11:8\u201314.","DOI":"10.1136\/gut.35.1.8"},{"key":"e_1_2_1_27_2","unstructured":"RichterJE&LongFJ. Cisapride for gastroesophageal reflux disease: a placebo\u2010controlled double\u2010blind study. Am J Gastroenterol1995;11:423\u201330."},{"key":"e_1_2_1_28_2","doi-asserted-by":"crossref","unstructured":"BaldiF Bianchi PorroG DobrillaG et al. Cisapride versus placebo in reflux esophagitis: a multicenter double\u2010blind trial. J Clin Gastroenterol1988;11(6):614\u20138.","DOI":"10.1097\/00004836-198812000-00007"},{"key":"e_1_2_1_29_2","unstructured":"LepoutreL VanderlindenI BollenG et al. Controlled study of cisapride in the treatment of grade II and III oesophagitis. Gastroenterology1987;11(2): A1501 (Abstract)."},{"key":"e_1_2_1_30_2","doi-asserted-by":"crossref","unstructured":"VigneriS TerminiR LeandroG et al.A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med1995;11:1106\u201310.","DOI":"10.1056\/NEJM199510263331703"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1997.00176.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.1997.00176.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T13:54:34Z","timestamp":1698414874000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.1997.00176.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,6]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1997,6]]}},"alternative-id":["10.1046\/j.1365-2036.1997.00176.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.1997.00176.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,6]]}}}